KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Inventory (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Inventory for 16 consecutive years, with $3.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Inventory rose 5.72% year-over-year to $3.2 billion, compared with a TTM value of $3.2 billion through Dec 2025, up 5.72%, and an annual FY2025 reading of $3.2 billion, up 5.72% over the prior year.
  • Inventory was $3.2 billion for Q4 2025 at Teva Pharmaceutical Industries, down from $3.3 billion in the prior quarter.
  • Across five years, Inventory topped out at $4.4 billion in Q1 2021 and bottomed at $3.0 billion in Q4 2024.
  • Average Inventory over 5 years is $3.8 billion, with a median of $4.0 billion recorded in 2024.
  • The sharpest move saw Inventory decreased 25.22% in 2024, then grew 5.72% in 2025.
  • Year by year, Inventory stood at $3.8 billion in 2021, then rose by 0.39% to $3.8 billion in 2022, then rose by 4.9% to $4.0 billion in 2023, then fell by 25.22% to $3.0 billion in 2024, then increased by 5.72% to $3.2 billion in 2025.
  • Business Quant data shows Inventory for TEVA at $3.2 billion in Q4 2025, $3.3 billion in Q3 2025, and $3.5 billion in Q2 2025.